Furthermore, in another meta-analysis [23], which excluded ELIXA [24] due to fact that lixisenatide is a short-acting GLP-1RA and all participants had acute coronary syndrome, GLP-1RAs were associated with significant reductions in MACE (HR 0.85, 95% CI 0.800.90), cardiovascular death (HR 0.85, 95% CI 0.780.93), stroke (HR 0.81, 95% CI 0.740.90), and myocardial infarction (HR 0.88, 95% CI 0.810.96) (Table 2)
For only $75/month , you get a medically supervised program that fits your lifestyle
Side effects calm down over time, still get sick feeling, indigestion and leg cramps now and again
While agonist peptides based on either scaffold are potent in rat obesity models 2,10,11,12,13 , only a transient weight loss effect is observed with sCT in mouse diet-induced obesity (DIO) models 14 , indicating that there may be distinctions in the mode of action of individual dual agonists